Drug Pricing Initiatives: Discussion continues in Congress and among stakeholders of drug pricing reform measures, including those that were originally part of H.R. 5376 (the Build Back Better Act, or BBBA).

Sources: Politico Pro (link, link), InsideHealthPolicy (link, link), Bloomberg Law

MEDICAID DRUG REBATE PROGRAM (MDRP)

Co-Pay/PBM Accumulator Regulation Struck Down: On May 17, 2022, the US District Court for the District of Columbia vacated and set aside the portions of the December 2020 Medicaid final rule related to the price reporting treatment of manufacturer-sponsored patient programs, including co-pay assistance programs, when the patient’s health plan, or its pharmacy benefit manager (PBM), has implemented a so-called “accumulator adjustment program.” The case is PhRMA v. Becerra, No. 1:21-cv-01395 (D.D.C.).

As we have reported (Issues No. 2, No. 3, No. 18, and No. 27), the Pharmaceutical Research and Manufacturers of America (PhRMA) brought the underlying litigation against the government, alleging that the final rule “treats financial assistance manufacturers provide to patients as if such assistance were a price discount that the manufacturer instead provided to the patients’ health plans, unless the manufacturer somehow ‘ensures’ that no health plan retroactively takes the benefits that the manufacturer intended for and provided to patients through the imposition of an accumulator adjustment program.” PhRMA asserted that this approach “contradicts the Medicaid rebate statute’s plain text,” specifically with respect to the statute’s best price definition.

The court agreed with PhRMA, explaining: “A manufacturer’s financial assistance to a patient does not qualify as a price made available from a manufacturer to a best-price-eligible purchaser. Rather, a manufacturer’s financial assistance is available from the manufacturer to the patient. And a patient is not a best-price-eligible purchaser.” The court added that “[f]easibility concerns support this conclusion,” as the rule “would make the calculation of the best price turn on information often in the sole possession of commercial health insurers” and that “manufacturers would need to conduct transaction-by-transaction investigations into the operations of accumulator adjustment programs even though manufacturers have
no control over (and sometimes no information) concerning those programs.” The government has 60 days to file an appeal. 

**Sources:** Law360, Bloomberg Law, STAT, BioWorld, Reuters, Endpoints News

### 340B PROGRAM

**Contract Pharmacy Updates:** Litigation related to manufacturer contract pharmacy policies continued, with the government filing an appeal in United Therapeutics Corp. v. Espinosa, No. 21 cv 1686 (DLF) (D.D.C.) and Novartis Pharm. Corp. v. Espinosa, No. 21-cv-1479 (DLF) (D.D.C.). For more information on the court decision in these cases, see Issue No. 14 of this digest.

**Sources:** STAT, Bloomberg Law (link, link), Law360, 340B Report (link, link, link)

### MEDICARE PART B

No developments to report.

### STATE LAW DEVELOPMENTS

State law developments related to the 340B program and the regulation of PBMs and manufacturers occurred in Colorado, Michigan, and Connecticut.

**Source:** 340B Report (link, link, link)

---

If you have questions about the Drug Pricing Digest, please contact the Government Price Reporting team listed below or the Latham lawyer with whom you normally consult:

<table>
<thead>
<tr>
<th>Name</th>
<th>Email</th>
<th>Phone</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Christopher H. Schott</td>
<td><a href="mailto:chris.schott@lw.com">chris.schott@lw.com</a></td>
<td>+1.202.637.2208</td>
<td>Washington, D.C.</td>
</tr>
<tr>
<td>Stuart S. Kurlander</td>
<td><a href="mailto:stuart.kurlander@lw.com">stuart.kurlander@lw.com</a></td>
<td>+1.202.637.2169</td>
<td>Washington, D.C.</td>
</tr>
<tr>
<td>Eric C. Greig</td>
<td><a href="mailto:eric.greig@lw.com">eric.greig@lw.com</a></td>
<td>+1.202.637.3330</td>
<td>Washington, D.C.</td>
</tr>
<tr>
<td>James M. Deal</td>
<td><a href="mailto:jamie.deal@lw.com">jamie.deal@lw.com</a></td>
<td>+1.202.637.2290</td>
<td>Washington, D.C.</td>
</tr>
<tr>
<td>Maria Malas</td>
<td><a href="mailto:maria.malas@lw.com">maria.malas@lw.com</a></td>
<td>+1.202.637.2334</td>
<td>Washington, D.C.</td>
</tr>
<tr>
<td>Lee B. Staley</td>
<td><a href="mailto:lee.staley@lw.com">lee.staley@lw.com</a></td>
<td>+1.617.880.4663</td>
<td>Boston</td>
</tr>
</tbody>
</table>

The Drug Pricing Digest is published by Latham & Watkins as a news reporting service to clients and other friends. Sources listed in this digest cannot be supplied by Latham & Watkins LLP and may require subscription access. The information contained in this publication should not be construed as legal advice. Should further analysis or explanation of the subject matter be required, please contact the lawyer with whom you normally consult. The invitation to contact is not a solicitation for legal work under the laws of any jurisdiction in which Latham lawyers are not authorized to practice. A complete list of Latham’s thought leadership publications can be found at [www.lw.com](http://www.lw.com). If you wish to update your contact details or customize the information you receive from Latham, visit our subscriber page.